Journal article

Phase II study of single agent capecitabine in the treatment of metastatic non-pancreatic neuroendocrine tumours

Abstract:: Background:This study sought to determine the safety of single agent capecitabine, a pro-drug of 5FU, in patients with metastatic non-pancreatic neuroendocrine tumours (NETs).Methods:Multicentre phase II, first-line study design. Oral capecitabine was administered on days 1-14 of 3-week cycles.Results:Treatment was safe and well tolerated. Common toxicities were diarrhoea and fatigue.Conclusion:The study provides evidence to support the use of capecitabine as a substitute for infusional 5FU in the management of NETs. © 2011 Cancer Research UK All rights reserved.

Actions

Email

Email this record

Send the bibliographic details of this record to your email address.

Your Email
Please enter the email address that the record information will be sent to.

-
Your message (optional)
Please add any additional information to be included within the email.
Cite

Cite this record

APA Style

Medley, L., Morel, A., Farrugia, D., Reed, N., Hayward, N., Davies, J., Kirichek, O., Thakker, R., & Talbot, D. (2011). Phase II study of single agent capecitabine in the treatment of metastatic non-pancreatic neuroendocrine tumours. British Journal of Cancer, 104(7), 1067–1070.

MLA Style

Medley, L., et al. “Phase II Study of Single Agent Capecitabine in the Treatment of Metastatic Non-Pancreatic Neuroendocrine Tumours.” British Journal of Cancer, vol. 104, no. 7, 2011, pp. 1067–70.

Chicago Style

Medley, L, A Morel, D Farrugia, N Reed, N Hayward, J Davies, O Kirichek, R Thakker, and D Talbot. 2011. “Phase II Study of Single Agent Capecitabine in the Treatment of Metastatic Non-Pancreatic Neuroendocrine Tumours.” British Journal of Cancer 104 (7): 1067–70.
Share
Print

Access Document

Publisher copy:: 10.1038/bjc.2011.76

Authors

+ Medley, L More by this author

Role:: Author

+ Morel, A More by this author

Role:: Author

+ Farrugia, D More by this author

Role:: Author

+ Reed, N More by this author

Role:: Author

+ Hayward, N More by this author

Role:: Author

More authors...

Journal:: British Journal of Cancer More from this journal
Volume:: 104
Issue:: 7
Pages:: 1067-1070
Publication date:: 2011-03-29
DOI:: 10.1038/bjc.2011.76
EISSN:: 1532-1827
ISSN:: 0007-0920

Language:: English
Keywords:: 5-fluorouracil

neuroendocrine tumour

capecitabine
Pubs id:: pubs:135222
UUID:: uuid:96a9027e-387a-4d7e-9dce-3bf078b734d2
Local pid:: pubs:135222
Source identifiers:: 135222
Deposit date:: 2012-12-19

Terms of use

Copyright date:: 2011

Licence:: Terms and Conditions of Use for Oxford University Research Archive

Views and Downloads

About views and downloads

If you are the owner of this record, you can report an update to it here: Report update to this record

TO TOP